Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | TP53 | P04637 | 3/20 | 0.70 |
| ▸ | HTT | P42858 | 3/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.62 |
| ▸ | RELA | Q04206 | 1/20 | 0.62 |
| ▸ | PNLIP | P16233 | 1/20 | 0.61 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13527434 | 0.88 | LMNA (0.66) | FFAR1LMNAMEN1KMT2ATP53 | |
| SCHEMBL19248942 | 0.86 | LMNA (0.65) | LMNAMEN1KMT2ATP53HTT | |
| SCHEMBL18132588 | 0.86 | FFAR1 (0.73) | FFAR1MEN1KMT2ATP53NR1H4 | |
| SCHEMBL19077945 | 0.85 | ALOX15 (0.68) | FFAR1LMNAMEN1KMT2ATP53 | |
| SCHEMBL18327174 | 0.85 | LMNA (0.89) | LMNAMEN1KMT2ATP53HTT | |
| SCHEMBL19248291 | 0.84 | KMT2A (0.73) | FFAR1LMNAMEN1KMT2ATP53 | |
| SCHEMBL5853912 | 0.83 | FFAR1 (0.69) | FFAR1MEN1KMT2ATP53HSD17B10 | |
| Salicylanilide SCHEMBL14051034 | 0.83 | MEN1 (1.00) | LMNAMEN1KMT2ATP53HTT | |
| Salicylanilide SCHEMBL20165864 | 0.83 | MEN1 (1.00) | LMNAMEN1KMT2ATP53HTT | |
| Salicylanilide SCHEMBL152221 | 0.83 | MEN1 (1.00) | LMNAMEN1KMT2ATP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2409569-B1 | Method for administering GLP-1 molecules | EMISPHERE TECH INC (US) | 2017-08-16 | — | — | EP | disclosed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| EP-1478233-B1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | EMISPHERE TECH INC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2015-07-23 | — | — | US | disclosed |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2015-07-23 | — | — | US | disclosed |
| US-8785381-B2 | Oral GLP-1 formulations | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785381-B2 | Oral GLP-1 formulations | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8492330-B2 | Formulation comprising GLP-1 | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492330-B2 | Formulation comprising GLP-1 | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-7727558-B2 | Polymeric delivery agents and delivery agent compounds | EMISPHERE TECHNOLOGIES, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7727558-B2 | Polymeric delivery agents and delivery agent compounds | EMISPHERE TECHNOLOGIES, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20100016229-A1 | Oral GLP-1 Formulations | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2010-01-21 | — | — | US | disclosed |
| US-20100016229-A1 | Oral GLP-1 Formulations | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2010-01-21 | — | — | US | disclosed |
| US-20090286735-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2009-11-19 | — | — | US | disclosed |
| US-20090286735-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2009-11-19 | — | — | US | disclosed |
| US-20070141022-A1 | POLYMERIC DELIVERY AGENTS AND DELIVERY AGENT COMPOUNDS | EMISPHERE TECHNOLOGIES, INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070141022-A1 | POLYMERIC DELIVERY AGENTS AND DELIVERY AGENT COMPOUNDS | EMISPHERE TECHNOLOGIES, INC. | 2007-06-21 | — | — | US | disclosed |
| US-7208483-B2 | Polymeric delivery agents and delivery agent compounds | EMISPHERE TECHNOLOGIES, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208483-B2 | Polymeric delivery agents and delivery agent compounds | EMISPHERE TECHNOLOGIES, INC. (US) | 2007-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070141022-A1 | POLYMERIC DELIVERY AGENTS AND DELIVERY AGENT COMPOUNDS | LPXN, PGF, TTPA | FFAR1 3173/4885LMNA 707/4885MEN1 3063/4885 |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | FFAR1 76/4885LMNA 4030/4885MEN1 776/4885 |
| US-20090286735-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | FFAR1 76/4885LMNA 4030/4885MEN1 776/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | FFAR1 2107/4885LMNA 4376/4885MEN1 3557/4885 |
| US-20100016229-A1 | Oral GLP-1 Formulations | GLP1R, GIPR, GCGR | FFAR1 120/4885LMNA 3528/4885MEN1 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.